Suiqing Zhou

Key Laboratory Of Liver Transplantation, Key Laboratory Of Hepatobiliary Tumors, Jiangsu Provincial Medical Key Laboratory
Nanjing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Glutathione peroxidase 3 preserves hepatocyte mitochondrial quality control to enhance macrophage pro-regenerative phenotype during liver regeneration.

Glutathione peroxidase 3 preserves hepatocyte mitochondrial quality control to enhance macrophage pro-regenerative phenotype during liver regeneration.

Journal: Clinical and translational medicine
Published: January 07, 2026

JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1.

JOSD1 drives hepatocellular carcinoma malignancy by modulating the ubiquitination-lactylation switch on PGAM1.

Journal: Gut
Published: October 20, 2025

Landscape screening identifies the lactate-modifying enzyme AARS2 as a master regulator and therapeutic target in hepatocellular carcinoma.

Landscape screening identifies the lactate-modifying enzyme AARS2 as a master regulator and therapeutic target in hepatocellular carcinoma.

Journal: Gut
Published: October 20, 2025

Lactate metabolism and lactylation in cancer: from pathogenesis to therapeutic advances.

Lactate metabolism and lactylation in cancer: from pathogenesis to therapeutic advances.

Journal: Signal transduction and targeted therapy
Published: December 19, 2024

Ciprofol exerts anti-tumour effects in hepatocellular carcinoma through the Raf-MEK-ERK signalling pathway.

Ciprofol exerts anti-tumour effects in hepatocellular carcinoma through the Raf-MEK-ERK signalling pathway.

Journal: Translational gastroenterology and hepatology
Published: September 19, 2024

Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma.

Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma.

Journal: Human cell
Published: August 19, 2024

eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.

eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.

Journal: Journal of hepatology
Published: July 02, 2024

GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its molecular mechanism in malignant progression.

GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its molecular mechanism in malignant progression.

Journal: British journal of cancer
Published: March 20, 2024

CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.

CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.

Journal: Cancer letters
Published: December 12, 2023

Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis.

Hepatocyte Deubiquitinating Enzyme OTUD5 Deficiency is a Key Aggravator for Metabolic Dysfunction-Associated Steatohepatitis by Disturbing Mitochondrial Homeostasis.

Journal: Cellular and molecular gastroenterology and hepatology
Published: August 12, 2023

Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma.

Hypomethylation-enhanced CRTC2 expression drives malignant phenotypes and primary resistance to immunotherapy in hepatocellular carcinoma.

Journal: iScience
Published: July 19, 2023

Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.

Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.

Journal: Journal of hepatology
Published: March 23, 2023
Showing 1-12 of 15

Last Updated: 09/26/2026